Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c
May 6, 2016 7:15 AM EDTAvalanche Biotechnologies (NASDAQ: AAVL) reported Q1 EPS of ($0.57), $0.18 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $265 thousand versus the consensus estimate of $400 thousand.
For earnings history and earnings-related data on Avalanche Biotechnologies (AAVL) click here.
... More


